Baxter International Inc.

National Research Council of Canada

Wellstat Vaccines, LLC

Baxter Healthcare Sa

The Rockefeller University

Inventprise, LLC

North American Vaccine, Inc.

Harvard College

University System of Maryland

The Brigham and Women's Hospital, Inc.

Affinivax, Inc.

Pfizer Ireland Pharmaceuticals

Francis Michon

Harold J Jennings

Samuel J Wohlstadter

Joseph Y Tai

Milan S Blake

Kuishu Ren

Robert Pon

Frank Comer

Michele Lussier

Charles Quentin Davis

Aaron S Haleva

Samuel L Moore

Catherine Uitz

Subhash V Kapre

John B Zabriskie

Glen Otero

Peter C Fusco

Iver Heron

Dennis L Kasper

Richard Malley

George Rainer Siber

Christopher L Penney

Shu-Mei Liang

Teresa J Broering

Donna Ambrosino

Alan S Cross

Raphael Simon

Jeffrey K Pullen

Vince Pozsgay

Sharon Tennant

Peter Fusco

Anello J D'Ambra

Robert J Chalifour

Robert Feldman

Martial Lacroix

John Kim

Mary Ellen Polvino-Bodnar

Conceicao Minetti

Catherine Dong

Arun Sarkar

Alan Cross

Technologies for the prevention and/or treatment of nosocomial infections.

Immunogenic compositions

A compound comprising one or more polysaccharide moieties each independently represented by the formula &#x3b2;(1&#x2192;4)-[GlcNH&#x2014;R]-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

Antibodies targeted to fungal cell wall polysaccharides

A system and method for assessing the immunological status of one or more individuals in a patient population is presented. The method includes establishing a database comprising a plurality of records of information each representative of the immune status of an individual in the population, each of said records including (1) current information from one or more assays for the presence of a biochemical, and (2) individual specific information comprising one or more of said individual's medical history, said individual's doctors' observations and historical, demographic, lifestyle, and familial information relating to said individual. The method further includes processing the information in said database to find trends or patterns relating to the immune status of individuals in said patient population; and using the said trends or patterns as part of a health care related decision making process.

Automated systems and methods for obtaining, storing, processing and utilizing immunologic information of an individual or population for various uses

This invention is directed to composition, vaccines, tools and methods in the treatment and prevention of. In particular, the invention is directed to a three-pronged approach that involves removal of the nonessential vaccine components, use of a nondenatured, genetically detoxified mutant, and adding virulence factors.

Bordetella pertussis immunogenic vaccine compositions

A compound comprising one or more polysaccharide moieties each independently represented by the formula &#x3b2;(1&#x2192;4)-[GlcNH-R]-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.

[object Object]

This invention relates to improved methods for purifying polysaccharides from cellular components, such as a cell wall. The method relates to hydrolyzing and separating the polysaccharides, thereby resulting in purified polysaccharides useful for producing antigens, antibodies, and vaccines comprising the polysaccharides alone or conjugated to carrier molecules. This method is simple, rapid, efficient, scalable, and reproducible.

Method for purifying polysaccharides

Automated systems and methods for obtaining, storing, processing and utilizing immunologic information of individuals and populations for various uses

A system and method for assessing immunological status of individuals and populations is presented. The method includes establishing a database containing a plurality of records, each record containing information representative of the immune status of an individual, including (1) bioassay results, and (2) individual specific information such as, medical history, clinical observations and historical, demographic, lifestyle, and familial/genetic information. By processing the information trends and/or patterns are obtained correlating various variables in the records across an individual, population or sub-population. The identified trends and/or patterns can, for example, be used in health care related decision making. In exemplary embodiments such processing can include generating a set of correlations and for each correlation generating a set of explanatory or relevant hypotheses. Then, for example, each hypothesis can be automatically refuted or supported, to the extent possible. The identified correlations, their associated hypotheses and the results of such automated vetting can then be reported to a user.

Systems and methods for obtaining, storing, processing and utilizing immunologic and other information of individuals and populations

The present invention provides, among other things, improved carrier proteins for antigen-based vaccines, including polysaccharide-based vaccines. An aspect of the invention advantageously employs tetanus toxin Fragment C.

Carrier proteins for vaccines

This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently linked to protein or liposomes to form immunogenic conjugates. The method of immunization for this invention comprises administering to an individual an immunogenic amount of group A polysaccharide. The group A polysaccharide may be administered as a vaccine either on its own, conjugated to proteins or conjugated to liposomes. Additionally, the group A polysaccharides may be associated with an adjuvant. This invention is particularly useful for providing both active and passive immunogenic protection for those populations most at risk of contracting group A Streptococcal infections and disease namely adults, pregnant women and in particular infants and children.

Group A streptococcal polysaccharide immunogenic compositions and methods

This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector. In addition, the invention also provides a method of using the non-toxic, modified pneumolysin toxoid in order to stimulate antibodies against in a treated individual which are then isolated and transferred to a second individual, thereby conferring protection against in the second individual.

Modified immunogenic pneumolysin compositions as vaccines

Disclosed is an type b polysaccharide-meningococcal outer membrane protein conjugate, pharmaceutical compositions thereof, and the use thereof to induce an immune response to in an animal.

Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide

Growing community of inventors

Bethesda, MD, United States of America

Francis Michon